CARA Cara Therapeutics, Inc.

11.95
+0.52  (4.55%)
Previous Close 11.43
Open 11.49
Price To book 4.34
Market Cap 326.02M
Shares 27,282,000
Volume 1,255,568
Short Ratio 6.41
Av. Daily Volume 1,351,820

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiated September 2015. Placed on clinical hold February 2016. Clinical hold released April 2016 with enrolment resuming June 2016. Interim conditional power analysis due 1H 2017.
IV CR845
Acute pain
Phase 2b trial initiated September, 2016. Data are due 1H 2017.
CR845
Osteoarthritis (OA)
Phase 2/3 completion of enrollment announced November 29, 2016 with top-line data due 1Q 2017.
IV CR845
Uremic pruritus

Latest News

  1. This Little Biotech Could Have a Big Winner on Its Hands
  2. Top 4 Medicinal Marijuana Stocks for 2017
  3. Donald Trump On Weed Legalization: What’s In Store For Marijuana Stocks?
  4. ETFs with exposure to CARA Therapeutics, Inc. : January 11, 2017
  5. The 2016 Election Was A Tipping Point For Marijuana Stocks
  6. 3 Companies Whose Revenue Could Double in 2017
  7. Will 2017 Be a Breakout Year for Cara Therapeutics?
  8. How Does Cara Therapeutics Inc (CARA) Stack Up Against Its Peers?
  9. The Worst Marijuana Stocks in 2016
  10. Cara Therapeutics Completes Planned Enrollment of Eight-Week Multi-Dose Phase of Adaptive Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
  11. The Unsurprising Reason Cara Therapeutics Fell Over 16% Today
  12. Cara Therapeutics to Webcast Presentation at the 28th Annual Piper Jaffray Healthcare Conference
  13. No to Closed-End Muni Bond Funds; Cara on a Run: Best of Kass
  14. Here's Why Cara Therapeutics Rose as Much as 25% Today
  15. CARA THERAPEUTICS, INC. Financials
  16. Q3 2016 Cara Operations Ltd Earnings Release - After Market Close
  17. Cara Therapeutics to Webcast Presentation at the Stifel 2016 Healthcare Conference
  18. Cara Therapeutics 3Q Loss 42 Cents a Share (CARA)
  19. CARA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  20. Cara Therapeutics Reports Third Quarter 2016 Financial Results